# An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07293754/  
OnCo record `nct07293754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RPTR-1-201 in advanced solid tumours, run by Repertoire Immune Medicines, now recruiting.

## Summary

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07293754 by Repertoire Immune Medicines, with 150 participants planned, started 2025-12-12 and due to reach its primary completion in 2028-12-15. Interventions recorded: RPTR-1-201 and PD-1 / PD-L1 monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07293754
- Phase: 1/2
- Setting: A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
- Sponsor: Repertoire Immune Medicines
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07293754: https://clinicaltrials.gov/study/NCT07293754

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07293754.json